HomeInsightsStock Comparison

Poly Medicure Ltd vs Suven Life Sciences Ltd Stock Comparison

Poly Medicure Ltd vs Suven Life Sciences Ltd Stock Comparison

Last Updated on: Jun 27, 2025

Key Highlights

  • The Latest Trading Price of Poly Medicure Ltd is ₹ 2180 as of 27 Jun 09:20.
  • The P/E Ratio of Poly Medicure Ltd changed from 21.7 on March 2020 to 59 on March 2024 . This represents a CAGR of 22.15% over 5 yearsThe P/E Ratio of Suven Life Sciences Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 years.
  • The Market Cap of Poly Medicure Ltd changed from ₹ 2079 crore on March 2020 to ₹ 15247 crore on March 2024 . This represents a CAGR of 48.96% over 5 yearsThe Market Cap of Suven Life Sciences Ltd changed from ₹ 272.38 crore on March 2020 to ₹ 2174 crore on March 2024 . This represents a CAGR of 51.50% over 5 years.
  • The revenue of Poly Medicure Ltd for the Mar '25 is ₹ 467.41 crore as compare to the Dec '24 revenue of ₹ 447.73 crore. This represent the growth of 4.4% The revenue of Suven Life Sciences Ltd for the Mar '25 is ₹ 2.69 crore as compare to the Dec '24 revenue of ₹ 3.24 crore. This represent the decline of -16.98%.
  • The ebitda of Poly Medicure Ltd for the Mar '25 is ₹ 146.05 crore as compare to the Dec '24 ebitda of ₹ 138.06 crore. This represent the growth of 5.79% The ebitda of Suven Life Sciences Ltd for the Mar '25 is ₹ -42.6 crore as compare to the Dec '24 ebitda of ₹ -37.58 crore. This represent the growth of 13.36%.
  • The net profit of Poly Medicure Ltd changed from ₹ 62.7 crore to ₹ 91.83 crore over 8 quarters. This represents a CAGR of 21.02% The net profit of Suven Life Sciences Ltd changed from ₹ -24.09 crore to ₹ -43.94 crore over 8 quarters. This represents a CAGR of 35.06% .
  • The Dividend Payout of Poly Medicure Ltd changed from 19.1 % on March 2020 to 11.44 % on March 2024 . This represents a CAGR of -9.74% over 5 yearsThe Dividend Payout of Suven Life Sciences Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Poly Medicure Ltd

  • Poly Medicure Limited was incorporated on March 30, 1995.
  • The Company is a manufacturer/producer of Medical Devices.
  • It manufactures and supply, in India and internationally, a diverse portfolio of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices and others. The Company's product portfolio comprises of more than 130 SKUs of medical devices in the product verticals of infusion therapy, oncology, anesthesia and respiratory care, urology, gastroenterology, blood management and blood collection, surgery and wound drainage, dialysis, central venous access catheters, veterinary medical devices, and others.

About Suven Life Sciences Ltd

  • Suven Life Sciences Limited (Formerly known as Suven Pharmaceuticals Ltd) was incorporated in March, 1989.
  • The Company changed its name from Suven Pharmaceuticals Limited to Suven Life Sciences Limited in September, 2003.
  • Promoted by Sudharani Jasti and Venkateswarlu Jasti, the Company began operations in 1989 as specialty chemicals provider. The Company is a clinical-stage biopharmaceutical company focused on the acquisition, development and commercialization of novel therapeutics for the treatment of neurodegenerative disorders.
  • Suven has a wholly owned subsidiary, Suven Neurosciences, Inc., USA, focused on clinical development activities of Suven molecules from phase 2, Proof-of-Concept (POC) studies. The Company is in the business of Contract Research And Manufacturing Services (CRAMS), catering to the needs of global life science industry and fine chemical majors.

Poly Medicure Ltd News Hub

News

Board of Poly Medicure recommends final dividend

Poly Medicure announced that the Board of Directors of the Company at its meeting held on ...

Read more

07 May 2025 09:36

News

Poly Medicure to announce Quarterly Result

Poly Medicure will hold a meeting of the Board of Directors of the Company on 6 May 2025. ...

Read more

29 Apr 2025 15:11

News

Poly Medicure incorporates wholly owned subsidiary - Polyhealth

Poly Medicure has incorporated a wholly owned Step down subsidiary named Polyhealth in Eng...

Read more

05 Feb 2025 19:19

News

Poly Medicure Ltd leads gainers in 'A' group

NLC India Ltd, Prudent Corporate Advisory Services Ltd, Redtape Ltd and Nuvama Wealth Mana...

Read more

04 Feb 2025 12:00

News

Poly Medicure spurts as PAT climbs 31% YoY to Rs 85 crore in Q3

The revenue growth was driven by the firm's robust market presence and effective growth st...

Read more

04 Feb 2025 14:20

News

Poly Medicure to discuss results

Poly Medicure will hold a meeting of the Board of Directors of the Company on 3 February 2...

Read more

27 Jan 2025 17:11

Suven Life Sciences Ltd News Hub

News

Suven Life Sciences Ltd Slides 3.06%, BSE Healthcare index Shed 1.34%

Suven Life Sciences Ltd fell 3.06% today to trade at Rs 220. The BSE Healthcare index is d...

Read more

23 Jun 2025 09:30

News

Suven Life Sciences to conduct AGM

Suven Life Sciences announced that the 36th Annual General Meeting(AGM) of the company wil...

Read more

14 May 2025 11:52

News

Suven Life Sciences schedules EGM

Suven Life Sciences announced that an Extra Ordinary General Meeting (EGM) of the Company ...

Read more

14 May 2025 11:52

News

Suven Life Sciences to declare Quarterly Results

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 13 May...

Read more

07 May 2025 10:54

News

Suven Life Sciences to convene board meeting

Suven Life Sciences will hold a meeting of the Board of Directors of the Company on 24 Jan...

Read more

17 Jan 2025 10:26

News

Suven Life spurts on initiating Phase-1 of clinical trial in US

SUVN-I6107, the fifth internally discovered compound from Suven to progress into clinical ...

Read more

08 Jan 2025 14:29

SWOT Analysis Of Suven Life Sciences Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Poly Medicure Ltd

Strength

5

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Suven Life Sciences Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Poly Medicure Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Poly Medicure Ltd and Suven Life Sciences Ltd

Which company has a larger market capitalization, Poly Medicure Ltd or Suven Life Sciences Ltd?

Market cap of Poly Medicure Ltd is 22,199 Cr while Market cap of Suven Life Sciences Ltd is 5,237 Cr

What are the key factors driving the stock performance of Poly Medicure Ltd and Suven Life Sciences Ltd?

The stock performance of Poly Medicure Ltd and Suven Life Sciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Poly Medicure Ltd and Suven Life Sciences Ltd?

As of June 27, 2025, the Poly Medicure Ltd stock price is INR ₹2190.95. On the other hand, Suven Life Sciences Ltd stock price is INR ₹240.15.

How do dividend payouts of Poly Medicure Ltd and Suven Life Sciences Ltd compare?

To compare the dividend payouts of Poly Medicure Ltd and Suven Life Sciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions